236 related articles for article (PubMed ID: 31813311)
1. New discoveries for an old drug: a review of recent olanzapine research.
Meftah AM; Deckler E; Citrome L; Kantrowitz JT
Postgrad Med; 2020 Jan; 132(1):80-90. PubMed ID: 31813311
[No Abstract] [Full Text] [Related]
2. Olanzapine-samidorphan combination tablets for the treatment of schizophrenia and bipolar I disorder - what is it, and will it be used?
Faden J; Serdenes R; Citrome L
Expert Rev Neurother; 2022 May; 22(5):365-376. PubMed ID: 35354374
[TBL] [Abstract][Full Text] [Related]
3. Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia.
Martin WF; Correll CU; Weiden PJ; Jiang Y; Pathak S; DiPetrillo L; Silverman BL; Ehrich EW
Am J Psychiatry; 2019 Jun; 176(6):457-467. PubMed ID: 30845818
[TBL] [Abstract][Full Text] [Related]
4. Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study.
Correll CU; Newcomer JW; Silverman B; DiPetrillo L; Graham C; Jiang Y; Du Y; Simmons A; Hopkinson C; McDonnell D; Kahn RS
Am J Psychiatry; 2020 Dec; 177(12):1168-1178. PubMed ID: 32791894
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and Short-term Safety of ALKS 3831, a Fixed-dose Combination of Olanzapine and Samidorphan, in Adult Subjects with Schizophrenia.
Sun L; McDonnell D; von Moltke L
Clin Ther; 2018 Nov; 40(11):1845-1854.e2. PubMed ID: 30348514
[TBL] [Abstract][Full Text] [Related]
6. Olanzapine/Samidorphan: New Drug Approved for Treating Bipolar I Disorder and Schizophrenia.
Monahan C; McCoy L; Powell J; Gums JG
Ann Pharmacother; 2022 Sep; 56(9):1049-1057. PubMed ID: 35040357
[TBL] [Abstract][Full Text] [Related]
7. Olanzapine dosing above the licensed range is more efficacious than lower doses: fact or fiction?
Citrome L; Kantrowitz JT
Expert Rev Neurother; 2009 Jul; 9(7):1045-58. PubMed ID: 19589053
[TBL] [Abstract][Full Text] [Related]
8. Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis.
Smith RC; Leucht S; Davis JM
Psychopharmacology (Berl); 2019 Feb; 236(2):545-559. PubMed ID: 30506237
[TBL] [Abstract][Full Text] [Related]
9. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
10. Quetiapine versus other atypical antipsychotics for schizophrenia.
Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia.
Meltzer HY; Bobo WV; Roy A; Jayathilake K; Chen Y; Ertugrul A; Anil Yağcioğlu AE; Small JG
J Clin Psychiatry; 2008 Feb; 69(2):274-85. PubMed ID: 18232726
[TBL] [Abstract][Full Text] [Related]
12. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems.
Mukundan A; Faulkner G; Cohn T; Remington G
Cochrane Database Syst Rev; 2010 Dec; (12):CD006629. PubMed ID: 21154372
[TBL] [Abstract][Full Text] [Related]
13. Betahistine effects on weight-related measures in patients treated with antipsychotic medications: a double-blind placebo-controlled study.
Smith RC; Maayan L; Wu R; Youssef M; Jing Z; Sershen H; Szabo V; Meyers J; Jin H; Zhao J; Davis JM
Psychopharmacology (Berl); 2018 Dec; 235(12):3545-3558. PubMed ID: 30382354
[TBL] [Abstract][Full Text] [Related]
14. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.
Newcomer JW
CNS Drugs; 2005; 19 Suppl 1():1-93. PubMed ID: 15998156
[TBL] [Abstract][Full Text] [Related]
15. Olanzapine: a new antipsychotic agent with efficacy in the management of schizophrenia.
Kando JC; Shepski JC; Satterlee W; Patel JK; Reams SG; Green AI
Ann Pharmacother; 1997 Nov; 31(11):1325-34. PubMed ID: 9391688
[TBL] [Abstract][Full Text] [Related]
16. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy and safety between amisulpride and olanzapine in schizophrenia treatment and a cost analysis in China: a systematic review, meta-analysis, and cost-minimization analysis.
Men P; Yi Z; Li C; Qu S; Xiong T; Yu X; Zhai S
BMC Psychiatry; 2018 Sep; 18(1):286. PubMed ID: 30185173
[TBL] [Abstract][Full Text] [Related]
18. Aripiprazole versus other atypical antipsychotics for schizophrenia.
Khanna P; Komossa K; Rummel-Kluge C; Hunger H; Schwarz S; El-Sayeh HG; Leucht S
Cochrane Database Syst Rev; 2013 Feb; (2):CD006569. PubMed ID: 23450570
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis.
Samara MT; Dold M; Gianatsi M; Nikolakopoulou A; Helfer B; Salanti G; Leucht S
JAMA Psychiatry; 2016 Mar; 73(3):199-210. PubMed ID: 26842482
[TBL] [Abstract][Full Text] [Related]
20. The role of olanzapine in the treatment of anorexia nervosa.
Dunican KC; DelDotto D
Ann Pharmacother; 2007 Jan; 41(1):111-5. PubMed ID: 17190846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
